Key Highlights
- Jonathan Crowther, Pfizer’s Head of Predictive Analytics, joins Lokavant Advisory Board.
- Aaron Mackey, PhD, appointed as Senior Vice President of AI and Data Science.
- Lokavant platform integrates real-time data to enhance clinical trial outcomes and efficiency.
Source: Business Wire
Notable Quotes
- “Aaron’s deep domain expertise in AI and data science will be instrumental in advancing Lokavant’s transformative technology,” – Jonathan Crowther, Head of Predictive Analytics at Pfizer
- “Lokavant is a really great fit for me. The combination of operational time series data and advanced, prescriptive analytics have tremendous power to fundamentally drive faster clinical research outcomes, surfacing insights using Lokavant’s proactive decision-support tools,” – Aaron Mackey, Senior Vice President of AI and Data Science at Lokavant
- “I’m excited to work with Aaron and the new advisory team to incorporate their learnings into our clinical trial intelligence platform and study feasibility applications,” – Rohit Nambisan, CEO and co-founder at Lokavant
SoHC's Take
Lokavant’s recent expansion in its advisory board and leadership reflects a strategic push towards enhancing the capabilities of its clinical trial intelligence platform. By integrating advanced analytics and predictive insights, Lokavant is poised to address the complex challenges of modern clinical trials. The addition of seasoned industry experts signifies a commitment to leveraging deep domain knowledge to innovate and drive efficiencies. This move could potentially set a new standard for how data is utilized in optimizing clinical trial processes, demonstrating the critical role of AI and data science in advancing healthcare technologies.
